Loading...
NPI 1053400655 · Cloquet, MN · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
White Drug Enterprises Inc is a community/retail pharmacy provider located in Cloquet, Minnesota. This profile covers 11 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | White Drug Enterprises Inc |
| Address | 707 Highway 33 S Ste 12 |
| City | Cloquet |
| State | MN |
| ZIP | 55720 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | October 12, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $172.6K |
| Medicaid | $47.1K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 550 | $140 | $77.9K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 330 | $80 | $25K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 550 | $40 | $20.7K |
| G0008 | Administration of influenza virus vaccine | 540 | $30 | $16.2K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 180 | $70 | $12.9K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 40 | $280 | $11.3K |
| 0124A | N/A | 80 | $40 | $3K |
| 0134A | N/A | 70 | $40 | $2.8K |
| G0009 | Administration of pneumococcal vaccine | 40 | $30 | $1.3K |
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 10 | $70 | $900 |
Showing 1–10 of 11
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 11 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99607 | After an initial 15 minutes, the pharmacist provides an additional 15–minutes of an in–person, patient–specific medication evaluation for a patient based on factors such as the patient’s history and… | 260 | $70 | $18.3K |
| 99606 | The pharmacist provides a 15–minute, in–person, patient–specific medication evaluation for an established patient based on factors such as the patient’s history and medication list. | 680 | $30 | $17.1K |
| 99605 | The pharmacist provides a 15–minute, in–person, patient–specific medication evaluation for a new patient based on factors such as the patient’s history and medication list. | 250 | $50 | $12.2K |
| 0011A | N/A | 50 | $0 | $0 |
| 0012A | N/A | 50 | $0 | $0 |
| 0013A | N/A | 40 | $0 | $0 |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 10 | $0 | $0 |
| 90653 | This code represents an inactivated influenza vaccine product that contains subunits of the virus and an adjuvant to enhance the immune response. The vaccine is administered via separately reportable… | 20 | $0 | $0 |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 10 | $0 | $0 |
| G0008 | Administration of influenza virus vaccine | 90 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Minnesota providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Minnesota median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99607 | After an initial 15 minutes, the pharmacist provides an additional 15–minutes of an in–person, patient–specific medication evaluation for a patient based on factors such as the patient’s history and… | 36 | 100 | 140 | $40 | $25K |
| 99606 | The pharmacist provides a 15–minute, in–person, patient–specific medication evaluation for an established patient based on factors such as the patient’s history and medication list. | 16 | 100 | 200 | $30 | $18.7K |
| 99605 | The pharmacist provides a 15–minute, in–person, patient–specific medication evaluation for a new patient based on factors such as the patient’s history and medication list. | 28 | 100 | 100 | $50 | $14.3K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 63 | 80 | 40 | $100 | $11.8K |
| 0011A | N/A | 86 | 170 | 50 | $50 | $9.9K |
| 0012A | N/A | 78 | 170 | 40 | $60 | $9.9K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 153 | 180 | 40 | $30 | $6.3K |
| 90653 | This code represents an inactivated influenza vaccine product that contains subunits of the virus and an adjuvant to enhance the immune response. The vaccine is administered via separately reportable… | 28 | 40 | 30 | $50 | $3.2K |
| 0013A | N/A | 22 | 50 | 30 | $30 | $2K |
| G0008 | Administration of influenza virus vaccine | 156 | 460 | 50 | $10 | $1.2K |
Other providers in the same ZIP code as White Drug Enterprises Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Fond Du Lac Reservation Business Committee | MN | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $28.7M |
| Fond Du Lac Reservation Business Committee | MN | Clinic/Center | $0 | $25.8M |
| County Of Carlton | MN | Case Management Agency | $0 | $13.7M |
| Split Rock Operations | MN | Assisted Living Facility | $0 | $8.5M |
| Community Memorial Hospital Association | MN | Critical Access Hospital | $0 | $4.3M |
| Cloquet Area Fire District | MN | Land Ambulance | $422.9K | $1.5M |
| Joey Vork | MN | Family Nurse Practitioner | $102.5K | $0 |
| Rhonda Johnson | MN | Physical Therapist | $38.8K | $0 |
| Karla Kukowski | MN | Physical Therapist | $37K | $0 |
| David Anderson | MN | Emergency Medicine Physician | $27K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.